EP Patent

EP4570804A1 — Pde4b inhibitor and use thereof

Assigned to Tibet Haisco Pharmaceutical Co Ltd · Expires 2025-06-18 · 1y expired

What this patent protects

A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of related diseases. Each group in formula (I) is …

USPTO Abstract

A compound represented by formula I, stereoisomers or pharmaceutically acceptable salts thereof, or a pharmaceutical composition containing same, and the use thereof as a PDE4B inhibitor in the preparation of a drug for treatment of related diseases. Each group in formula (I) is as defined in the description.

Drugs covered by this patent

Patent Metadata

Patent number
EP4570804A1
Jurisdiction
EP
Classification
—
Expires
2025-06-18
Drug substance claim
No
Drug product claim
No
Assignee
Tibet Haisco Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.